Amazon Enters $1 Billion Market as 'The New Place to Get It Up' Sending Hims Shares Plummeting

Amazon, the world's largest online retailer, has announced that it's expanding its product offerings to include erectile dysfunction medications. This strategic move is expected to send shockwaves through the industry and will undoubtedly change how American men tackle their performance in the bedroom.

The news has already had a significant impact on the stock market, as Hims, a popular telemedicine brand specializing in prescription-based ED treatments and Men's wellness products, saw its shares slump dramatically.

Amazon will be selling generic versions of top-selling ED medications such as sildenafil (the active ingredient in Viagra) and tadalafil (active in Cialis) as part of its efforts to tap into the lucrative $1 billion men's sexual wellness market. Of particular note is Amazon's 24/7 customer support feature for prescription medications, making it an attractive choice for those looking to handle these types of sensitive matters from the comfort and anonymity of their own homes.

These ED medications will be sold to customers with a prescription in the standard Amazon package - not only ensuring speedy delivery but also further ensuring customers' discretion and comfort. There's been no word on whether Amazon plans on discreetly labeling these packages, but considering its clientele's needs and their brand reputation, it's a step the company might soon take.

For the customers experiencing difficulty in this area, accessing affordable health care services is what should come first, said an Amazon spokesperson in an interview, 'We believe in making access to these products as seamless and cost-effective as possible while maintaining the strictest quality and safety standards.' It's worth mentioning that to buy these products on Amazon, users will have to complete an online questionnaire that assists in assessing their eligibility for these prescription-based medications.

This offering indicates that Amazon is doubling down on its plan to enter the billion-dollar healthcare market, especially after it bought One Medical last year for $3.9 billion.